Prefilled Auto Injectors Market is Poised to Grow at CAGR of 15% to Achieve USD 17 Billion by 2033

The Prefilled Auto Injectors Market in the United States accounted for more than 85% of the market share in the North American region in 2022. This dominance is expected to persist throughout the forecast period. The prevalence of diabetes and anaphylaxis in the country presents a significant opportunity for increased sales of prefilled auto injectors in the coming years.

Globally, the prefilled auto injectors market is poised for remarkable growth, with a robust compound annual growth rate (CAGR) of 15%. By the end of 2033, it is projected to reach a market value of US$ 17 billion, marking a substantial increase from its current size of US$ 4.2 billion.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=169

Restraints:

Pre-filled auto-injectors are relatively expensive compared to traditional injection methods. This can limit their adoption, particularly in regions where healthcare costs are a major concern.
Although pre-filled auto-injectors are designed to be safe and easy to use, there have been cases of device malfunctions, including needlestick injuries and dosing errors. Such incidents can negatively impact market growth and undermine patient trust.
The pre-filled auto-injectors market is highly regulated, with stringent requirements for safety, efficacy, and quality. Complying with these regulations can be time-consuming and expensive, which can limit the entry of new players into the market.
Some patients may prefer alternative drug delivery methods, such as oral medication or topical creams, over pre-filled auto-injectors. This preference can limit the demand for pre-filled auto-injectors and limit their market growth.

Some of the key market trends in the pre-filled auto-injectors market include:

There is an increasing trend towards personalized medicine, which involves tailoring medication to individual patient needs. Pre-filled auto-injectors are well-suited for personalized medicine as they allow for precise dosing and ease of administration.
Pre-filled auto-injectors are being designed with the patient in mind, with a focus on ease of use and minimizing pain and discomfort during injection. Some newer models offer features such as ergonomic designs, automatic needle insertion, and retracting mechanisms, which can improve patient comfort.
The use of biologics and biosimilars is on the rise, and pre-filled auto-injectors are the preferred delivery method for these medications. Biologics and biosimilars require precise dosing and administration, and pre-filled auto-injectors provide a reliable and convenient solution.
The pre-filled auto-injectors market is seeing an influx of new players, particularly from Asia-Pacific countries. These new players are bringing innovative products to the market and challenging established players with lower-priced alternatives.
There is a growing trend towards sustainability and eco-friendliness in the pre-filled auto-injectors market. Some companies are developing devices with recyclable components or biodegradable materials, which can help to reduce the environmental impact of these products.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

Antares Pharma Inc.
Eli Lilly Company
Terumo
Becton Dickinson and Company
Medtronic
Pfizer Inc.
Gerresheimer
Mylan N.V.
Amgen Inc.

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞:https://www.factmr.com/report/169/prefilled-auto-injectors-market

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

Key players in the prefilled auto injector market are prioritizing the development and introduction of innovative products to strengthen their market position and enhance sales prospects.

In May 2022, Jabil Healthcare, a division of Jabil Inc., unveiled a new modular auto injector platform designed to be more cost-effective than existing alternatives in the market. The launch aims to support sustainable drug delivery within the pharmaceutical industry.

In October 2021, Ypsomed, a leading medical device manufacturer, introduced the world's first auto injector for prefilled syringes with integrated connectivity. The YpsoMate On leverages the company's expertise in auto injector technology and provides new opportunities for digital therapy support.

In April 2020, Teva Pharmaceuticals USA Inc., a prominent pharmaceutical manufacturer, launched an auto injector device for AJOVY® (fremanezumab-vfrm) injection in the United States. The drug serves as a preventive treatment for migraines in adults.

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐏𝐫𝐞𝐟𝐢𝐥𝐥𝐞𝐝 𝐀𝐮𝐭𝐨 𝐈𝐧𝐣𝐞𝐜𝐭𝐨𝐫𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By Indication:
Anaphylaxis
Multiple Sclerosis
Rheumatoid Arthritis
Others

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

By Region:
North America
Latin America
Europe
APAC
MEA

Future sales of prefilled auto injectors are predicted to be primarily driven by rising interest in health and rising demand for drug self-administration. Also, the high prevalence of diabetes worldwide is anticipated to boost sales of prefilled insulin pens and prefilled insulin auto injectors during the course of the projection period (2023 to 2033).

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.